

5-2019

Rare Case of Adult Onset Pompe's Disease

Supriya Todkar
Henry Ford Health System

Mahalakshmi Honasoge
Henry Ford Health System

Follow this and additional works at: <https://scholarlycommons.henryford.com/merf2019caserpt>

Recommended Citation

Todkar, Supriya and Honasoge, Mahalakshmi, "Rare Case of Adult Onset Pompe's Disease" (2019). *Case Reports*. 23.
<https://scholarlycommons.henryford.com/merf2019caserpt/23>

This Poster is brought to you for free and open access by the Medical Education Research Forum 2019 at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Case Reports by an authorized administrator of Henry Ford Health System Scholarly Commons. For more information, please contact acabr4@hfhs.org.



Introduction

- Pompe's disease is a lysosomal storage disease characterized by accumulation of glycogen primarily in muscle tissue.
- Infantile and late onset are the two common forms of this disease.
- We present a case of adult onset disease in a patient with type 1 diabetes mellitus (DM) with involvement of muscle, liver and bone.

Case History

- A 28-year-old male was being followed up for type 1 diabetes mellitus. He had a long standing history of mild muscle weakness.
- Family history : Unknown muscle disorder in father and cardiomyopathy in grandfather.
- Previous work up showed elevated CPK levels of 1340 (reference range < 130IU/L) along with elevated transaminases.
- Muscle biopsy - Autophagic activity producing rimmed vacuole like structures in many of the muscle fibers, with increased staining of cytoplasm with Periodic acid Schiff.
- He was lost to follow up and about 10 years later decided to undergo further evaluation , which showed persistently elevated CPK levels.
- EMG studies which showed generalized myopathic process.
- Serum acid maltase level was found to be low.
- On Glucosidase alpha gene sequencing, he was found to have c.-32-13T>G and c.1655T>C (p. L552P) mutation.

Laboratory Data



Laboratory data before diagnosis

DATE	AST (Ref 15-35 IU/L)	ALT (Ref 30-65 IU/L)	CPK (Ref < 130 IU/L)
July 2017	138	178	1860
March 2009	224	210	1340
March 2008	249	184	1343
June 2007	216	191	
November 2006	164	175	

Laboratory data after initiation of enzyme replacement

DATE	AST (Ref 15-35 IU/L)	ALT (Ref 30-65 IU/L)	CPK (Ref < 130 IU/L)
July 2018	90	139	1125

Pathophysiology of Pompe's disease



Common mutation in adult onset Pompe's disease

Learning Points

- Late-onset Pompe's disease is a rare, progressive, autosomal recessive disorder; disease progression and symptomatology are variable between individuals, which delays the diagnosis.
- Use of ERT has substantially altered outcomes for the patients, underscoring the importance of early diagnosis with high index of suspicion.
- Additional impact of type 1 DM is of concern in our patient.
- Since glycogen hepatopathy is associated with uncontrolled Type 1 DM, tight control of diabetes may help to reduce the impact of acid alpha glucosidase deficiency.
- Improvement of bone density after ERT suggests need for further studies to elucidate the pathophysiology of bone involvement in this disorder.

References

- [Bone](#). 2010 Sep;47(3):643-9. doi: 10.1016/j.bone.2010.06.021. Epub 2010 Jun 25. [van den Berg LE1](#), [Zandbergen AA](#), [van Capelle CI](#), [de Vries JM](#), [Hop WC](#), [van den Hout JM](#), [Reuser AJ](#), [Zillikens MC](#), [van der Ploeg AT](#). Bone density in patients with late onset Pompe disease
- Consensus treatment recommendations for late-onset Pompe disease. [Muscle Nerve](#). 2012 Mar;45(3):319-33. doi: 10.1002/mus.22329. Epub 2011 Dec 15. [Cupler EJ1](#), [Berger KI](#), [Leshner RT](#), [Wolfe GI](#), [Han JJ](#), [Barohn RJ](#), [Kissel JT](#); [AANEM Consensus Committee on Late-onset Pompe Disease](#) Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density.
- [Int J Endocrinol Metab](#). 2012 Autumn; 10(4): 599–603. [George Papadimas,1,*](#) [Gerassimos Terzis,1,2](#) [Constantinos Papadopoulos,1](#) [Anna Areovimata](#)
- Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II. [Biochim Biophys Acta](#). 2003 Mar 20;1637(2):164-70. [Hesselink RP1](#), [Wagenmakers AJ](#), [Drost MR](#), [Van der Yusse GJ](#)